Summary
Guardant Health, Inc. (GH) has entered into a binding term sheet with Foundation Medicine, Inc. (FMI) to resolve all pending patent litigation concerning Guardant's digital sequencing technology patents. This agreement is a significant development as it provides a pathway to dismiss ongoing legal disputes. The proposed settlement includes a $25 million payment from FMI to Guardant Health, along with future royalty payments for the remaining term of the patents.
Key Highlights
- 1Guardant Health (GH) and Foundation Medicine (FMI) have entered a binding term sheet to settle all patent litigation regarding Guardant's digital sequencing technology.
- 2FMI will pay GH $25 million as part of the settlement.
- 3GH will receive certain royalties from FMI for the remaining term of the patents.
- 4GH will grant FMI a non-exclusive license to the disputed patents.
- 5The agreement aims to dismiss all pending patent litigation between the two companies.
- 6The settlement is subject to the execution of a definitive settlement agreement and potential court approval.
Frequently Asked Questions
The main outcome is the resolution of all pending patent litigation between Guardant Health and Foundation Medicine concerning Guardant's digital sequencing technology patents. This is achieved through a settlement that includes a financial payment and licensing arrangement.
Guardant Health will receive an upfront payment of $25 million from Foundation Medicine, as well as ongoing royalty payments for the duration of the patents.
Yes, Guardant Health will grant Foundation Medicine a non-exclusive license to its patents as part of the settlement.
The term sheet is binding, but the settlement is not yet finalized. It is subject to the execution of a definitive settlement agreement and potentially final court approval.